U.S. Markets closed

Neuralstem, Inc. (CUR)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.18+0.02 (+1.72%)
At close: 4:00PM EDT
People also watch
ATHXCYTXPSTIOPXAOSIR
  • P
    Pawel
    Pawel
    I have been doing some thinking about NSI-189 and Neuralstem's prospects. I am no longer invested here other than a miniscule position but I keep wondering what will happen to this enterprise - I have been following it for a couple of years after all.

    Regarding NSI, I learned more about SDQ (Symptoms of Depression Questionnaire), as NSI managed to reach statistical significance 40mg QD on that scale. Per my previous remarks, it is highly probable it is simply a false positive, a possibility corroborated by the failure to reach statistical significance on other scales and at different dosages. However, SDQ is designed to factor in other aspects of depression. In particular, it weighs heavily anxiety-related symptoms. It is possible that NSI is appropriate for the subset of depression caused by/comorbid with anxiety disorders. While at this point I am quite skeptical of the circulating anecdotal evidence, there were reports of NSI significantly ablating the stress response and doing so at 40mg dose rather than 80mg (anxiety and agitation at higher doses). It is possible that NSI does exhibit such a specific mode of action. Nonetheless, the simpler explanation is usually the better one so it is safer to assume that NSI is simply a crappy antidepressant. It really depends on what else there is in the data set but that remains to be seen.

    I suppose this Phase 2 trial is the first time that NSI-189 has been clinically characterized on a larger population and there are lessons to be learned there.
    I do believe that NSI has useful biological activity and that not all is lost here - this differentiates CUR from STEM. This study may pave the way to directing NSI toward its correct indications. However, that is going to take probably another 3 years and I do not think this company will last that long. What are your views on that? Would CUR be acquired or sell its assets and dissolve? They have like 10-15 employees so there really is not much to acquire beyond the IP. I would imagine it might be easier for another company just to buy the assets and develop them in their own house.

    What is your opinion of the management? This is the factor that will determine whether I will ever entrust this company with my money. Until the PR I had thought that Daly was doing a pretty good job and even now their finances are not too shabby. However, their actions after the release led to the huge loss of value that, IMHO, could have been avoided and/or spread over a few days, allowing people to minimize their losses. I understand that it is biotech and we should be ready for losing 90% of our investments but I do not appreciate any management facilitating such a loss and appear nonchalant about it rather than trying to alleviate it. Retail investors, unlike institutions, risk their own money. Lastly, in my opinion their risk management has been subpar; after the failure there was no clear Plan B, as far as I can tell, and the market responded accordingly.

    In any case, all of this is guesswork, which I find frustrating. We will learn something only in new press releases - I doubt we will be able to divine anything ahead of time. However, it is always good to exchange ideas and possibly gain a broader perspective and useful insight. GLTA.
  • d
    dog
    dog
    Looking like a bottom, but a fragile one best. Let's see some volume now with a break thru 16 and then .20 and I'll be buying more.
    dog
  • P
    Pawel
    Pawel
    Imagecrimestudio
  • H
    Haley
    Haley
    My guess is that CUR is due for a pullback in the short-run. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awe-som_sto-cks is the one i like best.
  • M
    Morgan
    Morgan
    Perhaps a short-term pull back is more likely before the next rally on CUR? awe-som*sto-cks just allerted a new stock - it beats having to dig online yourself for new stock ideas.
  • J
    JujuP
    JujuP
    AH = 1000 shares. Not much interest.
  • P
    Pawel
    Pawel
    So CUR will be able to sustain operations throughout 2018 - this is good news. I wonder why it was too difficult for them to have announced that the offering was closed a week ago in order to reassure its traumatized investors and stop bleeding. Judging by how their IR functions we can only surmise that the psychological well-being of their retail investors is not Neuralstem's priority ;-)

    We will hear an update on the corporate strategy in 4Q. What are your thoughts? My view is that unless CUR secures significant additional funding they will be bought out - all additional indications for NSI are in pre-clinical phases and it will take years to verify them. Any addtional MDD studies will take at least another 2 years. Cognition is anybody's guess. In any case, a buy-out seems like the most viable option at this point. |Given the wealth of directions to pursue it may even be on quite favorable terms.

    I also wonder at what level will SP stabilize for the forseeable future.

    Your thoughts?
  • j
    jim b
    jim b
    I've been reading some of the posts( yep, can't look away neither) and I can't help but think why would anyone be buying this stock, even at under a buck. Maybe I'm the stupidest guy here but I don't see anything left here. I came on board over 4 years ago when NSI 566 was all the rage with top line P2 data on the horizon. 189 was the next major thing in the pipeline, then stroke and spinal cord injury treatments. I remember the morning of the 566 results and in the pre market the price moved over 7 dollars ( $91 post split!). I thought I had a big one, then it all came crashing down. Now 189 crashed and burned too. That was over 4 years of time with 2 major indications with momentum. Guess I just don't see what others do or have the time, which will be years to wait for CUR. I think they had their shot and now their time is over. Just my hollow opinion.
  • S
    Steve
    Steve
    $0.08 pre-split.
  • J
    JujuP
    JujuP
    Dog Doo
  • J
    JujuP
    JujuP
    My question is, when did the new investors with $6 Million know about the failed results?
  • P
    Pawel
    Pawel
    For those still hurting after the NSI trials, have a look at OMER. It appears to be doing really well, is significantly derisked and on its way to greater SP. Not pumping, just trying to help.
  • j
    jim b
    jim b
    The cover story on Time magazine this week is about the huge need for new antidepressants from both pharma companies and depression sufferers. We just missed the big time guys! Sucks.
  • D
    Devin
    Devin
    just to get the spam pump off the top :)
  • P
    Paul
    Paul
    I can't believe how many idiots are still here still investing in CUR! Guys get a clue! YOU HAVE BEEN HAD!!!
  • d
    dog
    dog
    CVI - What does this mean? Could this mean they bought via the private placement offering?
    Does that confirm CUR has filled the PP?
    Anyway, I've started buying again.
  • J
    JujuP
    JujuP

    https://seekingalpha.com/article/4094360-neuralstem-doomed

    These guys seem to be in-tune with CUR, ever since March 2015 anyway

    Neuralstem Is Doomed
    Neuralstem's NSI-189 has failed to meet its primary endpoint. The company has poor liquidity and will rely on dilution. Eventually, Neuralstem will be de-listed
    seekingalpha.com
  • d
    dog
    dog
    Wow, looks like it was really good news. I am surprised at how quiet the board has become. I guess between trial narrow miss, shorts and paid bashers, most of the bulls are gone.
  • P
    Pawel
    Pawel
    Somebody e-mailed Danielle about offering and she responded that:

    "yes, offering was closed and all monies were transferred. There are no necessary documents needed for closing. The upcoming Q will reflect the transaction".

    I suppose these could be good news but I am not willing to gamble on this. Any thoughts?
  • d
    dog
    dog
    interesting close. Short covering or has the bottom set in. My bet is BOTH!